主页 > 医学文档 >
【科普】基因检测可预知肺癌患者对化疗的耐受
ScienceDaily (Aug. 28, 2009) — The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.
Ian Cree, from Queen Alexandra Hospital, Portsmouth, UK, led a team of researchers who assessed the chemosensitivity of a series of 49 NSCLC tumors and compared this with quantitative expression of putative resistance genes measured by RT-PCR. He said, "There was considerable heterogeneity between tumors, and while this showed no direct correlation with individual gene expression, there was strong correlation of multi-gene signatures for many of the single chemotherapy agents and combinations tested. This may allow the definition of predictive signatures to guide individualized chemotherapy in lung cancer".
The researchers tested docetaxel, cisplatin, gemcitabine and combinations of the agents on tumour cells taken from 49 fresh NSCLC samples. There were considerable differences between tumors in their sensitivity to individual agents and combinations, though the combination of cisplatin + gemcitabine was usually the most active.
When these results were compared to the gene expression in the tumors, Cree and his colleagues were able to identify a number of patterns, especially in chemosensitivity to combinations of treatments. Cree said, "The genes identified in this study fall into several categories, linked with much studied mechanisms such as metabolism within the cell, membrane drug pumps, and DNA repair, but also with apoptosis, suggesting that the general susceptibility of the cell to undergo this process may be an important determinant of tumor chemosensitivity, outweighing more specific mechanisms".
--------------------------------------------------------------------------------
Journal reference:
Sharon Glaysher, Dennis Yiannakis, Francis G Gabriel, Penny Johnson, Marta E Polak, Louise A Knight, Zoe Goldthorpe, Katharine Peregrin, Mya Gyi, Paul Modi, Joe Rahamim, Mark E Smith, Khalid Amer, Bruce Addis, Matthew Poole, Ajit Narayanan, Tim J Gulliford, Peter E Andreotti and Ian A Cree. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer, 2009; (in press) [link]
Adapted from materials provided by BioMed Central, via EurekAlert!, a service of AAAS.
http://www.sciencedaily.com/releases/2009/08/090826191847.htm 本人认领了，48h内翻译 Gene Assay To Help To Predict Lung Cancer Treatment Resistance
基因检测可预测肺癌患者对化疗的耐药程度
ScienceDaily (Aug. 28, 2009) — The genes that may contribute to drug resistance in non-small
每日科学杂志（2009.8.28）——可能导致对非小细胞肺癌化疗药耐药的基因已可以预测。
cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC
一篇位于BMC癌症杂志首页的文章写到，研究者发现，
Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.
那些认为会导致对化疗药敏感和耐药的基因与实际的体外化疗敏感性有很大的相关程度。
Ian Cree, from Queen Alexandra Hospital, Portsmouth, UK, led a team of researchers who
英国朴次茅斯市，亚历山大皇后医院的Ian Cree，领导了一个研究团队，
Assessed the chemosensitivity of a series of 49 NSCLC tumors and compared this with
评估了一系列（49个）非小细胞肺癌患者的化学敏感性，
quantitative expression of putative resistance genes measured byRT-PCR
利用逆转录聚合酶链反应测定已假设存在的耐药基因表达数量，并将两者进行比较。
He said, "There was considerable heterogeneity between tumors, and while this showed no direct correlation with individual gene expression,
他说：“各肿瘤有显著的异质性，这种异质性并非与个人基因表达有直接联系
there was strong correlation of multi-gene signatures for many of the single chemotherapy agents and combinations tested.
然而有多种基因标志物，与对单个化疗药物和联合化疗药的测试结果，有强烈的相关性。This may allow the definition of predictive signatures to guide individualized chemotherapy in lung cancer".
也许这种预测标志物的定义，可以知道个体化的肺癌化疗。“
The researchers tested docetaxel, cisplatin, gemcitabine and combinations of the agents on
tumour cells taken from 49 fresh NSCLC samples.
研究者测试时，用多烯紫杉醇，顺铂，吉西他滨和联合用药治疗49例新发的NSCLC样本。There were considerable differences between tumors in their sensitivity to individual agents and combinations, though the combination of cisplatin + gemcitabine was usually the most active.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-09-26 17:11
医学,生命科学网